Reviva Pharmaceuticals

Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus expectations on the bottom line, with a Net Loss of $2.45M compared to the $4.31M expected. GAAP EPS of -$0.19 outperformed the -$0.36 consensus, driven by a 62.6% YoY reduction in R&D expenses as clinical activities shifted toward regulatory prep. Cash reserves increased to $19.9M, providing a runway to support planned Bioequivalence studies in Q4 2026, though patient enrollment for the Phase 3 RECOVER-2 trial remains contingent on securing additional financing in 1H 2027.